Filtered By:
Management: Marketing
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 200 results found since Jan 2013.
Consumer-Led Screening for Atrial Fibrillation: Frontier Review of the AF-SCREEN International Collaboration
Circulation. 2022 Nov 8;146(19):1461-1474. doi: 10.1161/CIRCULATIONAHA.121.058911. Epub 2022 Nov 7.ABSTRACTThe technological evolution and widespread availability of wearables and handheld ECG devices capable of screening for atrial fibrillation (AF), and their promotion directly to consumers, has focused attention of health care professionals and patient organizations on consumer-led AF screening. In this Frontiers review, members of the AF-SCREEN International Collaboration provide a critical appraisal of this rapidly evolving field to increase awareness of the complexities and uncertainties surrounding consumer-led AF s...
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Axel Brandes Stavros Stavrakis Ben Freedman Sotiris Antoniou Giuseppe Boriani A John Camm Clara K Chow Eric Ding Johan Engdahl Michael M Gibson Gregory Golovchiner Taya Glotzer Yutao Guo Jeff S Healey Mellanie T Hills Linda Johnson Gregory Y H Lip Trudie Source Type: research
RapidPulse Raises Additional Funding for Ischemic Stroke Therapies and Notes Promising Results
MIAMI, Sept. 13, 2022 -- (Healthcare Sales & Marketing Network) -- RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced that it has raised an additional $10.5 million, bri... Devices, Interventional, Neurology, Venture Capital RapidPulse, Cyclic Aspiration System, stroke
Source: HSMN NewsFeed - September 13, 2022 Category: Pharmaceuticals Source Type: news
Climate Experts Are Testing New Ways To Reach the People Most Affected by Extreme Heat
As heat waves become longer, hotter, and more widespread across the planet, human responses to them are becoming increasingly local and specialized.
Both scientific researchers and government officials are finding that the best strategies to keep cool are ones that are specially tailored to a community. That may seem obvious, given that outdoor laborers need different cooling resources than school teachers, for instance. But existing national and regional policies aren’t always that fine tuned—and they run the risk of wasting resources or missing the most vulnerable people.
[time-brightcove not-tgx=”tru...
Source: TIME: Health - July 19, 2022 Category: Consumer Health News Authors: Emily Barone Tags: Uncategorized climate climate change Climate Is Everything extreme weather healthscienceclimate Source Type: news
MicroTransponder Raises $53M, Appoints New CEO
AUSTIN, Texas, June 20, 2022 -- (Healthcare Sales & Marketing Network) -- MicroTransponder®, Inc. closed an oversubscribed $53 million Series E funding round led by US Venture Partners (USVP), a multi-stage investment firm. GPG Ventures and Exceller H... Devices, Neurology, Personnel, Venture Capital MicroTransponder, Vivistim, stroke
Source: HSMN NewsFeed - June 20, 2022 Category: Pharmaceuticals Source Type: news
Conformal Medical Announces Launch of CONFORM Pivotal Trial
Study to support U.S. FDA approval of the novel CLAAS® implant for left atrial appendage occlusion (LAAO) and stroke prevention
NASHUA, N.H., June 17, 2022 -- (Healthcare Sales & Marketing Network) -- Conformal Medical, Inc., a medical device compa... Devices, Interventional, Cardiology Conformal Medical, CLAAS System, atrial fibrillation, LAAO
Source: HSMN NewsFeed - June 17, 2022 Category: Pharmaceuticals Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
FDA safety warnings and trends in testosterone marketing to physicians
In this study, we found that testosterone marketing efforts such as marketing spending per encounter, quarterly marketing spending per physician, and quarterly number of encounters per physician increased among non-PCPs and urban physicians for 4 quarters following an FDA boxed warning in 2015 on testosterone prescriptions. After the black box warning, off-label testosterone advertisements stopped. This reduction in advertising could have made it more attractive for pharmaceutical companies to increase their marketing spending targeting non-PCPs and physicians in urban areas. Understanding responses of pharmaceutical compa...
Source: The American Journal of Managed Care - April 11, 2022 Category: Health Management Authors: Adeniyi Togun Ashwini Sankar Pinar Karaca-Mandic Source Type: research
Flinn Foundation commits $5.52M to College of Medicine – Phoenix
The gift will establish two research faculty positions and support training to further translational research in cardiovascular diseases, neurosciences and mental health.
April 7, 2022
University Alumni and Development Programflinn-gift-web.jpg
Lauren MacDonnell, a research associate in the Translational Cardiovascular Research Center, processes samples in the TCRC lab.
Sun Belous/College of Medicine – Phoenix Marketing and CommunicationsHealthCollege of Medicine - PhoenixCollege of PharmacyCompassion
Media contact(s)Beth Smith
College of Medicine – Phoenixbhsmith1@arizona.edu602-827-2676TheFlinn Foundation has...
Source: The University of Arizona: Health - April 6, 2022 Category: Universities & Medical Training Authors: mittank Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
MicroTransponder(R) Receives FDA Approval for Breakthrough Device Benefiting Stroke Survivors
The first-of-its-kind Vivistim® Paired Vagus Nerve Stimulation (VNS) System significantly improves upper limb rehabilitation therapy
DALLAS, Aug. 31, 2021 -- (Healthcare Sales & Marketing Network) -- MicroTransponder, Inc. today announced United St... Devices, Neurology, FDA MicroTransponder, Vivistim Paired VNS System, Vagus Nerve Stimulation, stroke
Source: HSMN NewsFeed - August 31, 2021 Category: Pharmaceuticals Source Type: news
An emulated target trial analysis based on Medicare data suggested non-inferiority of Dabigatran versus Rivaroxaban
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular heart chamber beatings. It affects three to six million people in the U.S.1, among whom 85% to 90% are eligible for oral anticoagulation therapies2,3. As established in the literature, it is of great interest to properly choose among non-vitamin K antagonist oral anticoagulants (NOACs). Rivaroxaban and Dabigatran were approved by the U.S. FDA in November 2011 and October 2010, respectively. They were the first two NOACs for preventing stroke for non-valvular AF patients and have been widely used since marketing.
Source: Journal of Clinical Epidemiology - July 13, 2021 Category: Epidemiology Authors: Hao Mei, Jiping Wang, Shuangge Ma Source Type: research
